PET FDG studies in oncology

Nuclear Medicine and Biology

Volumn 21, Issue 5, 1994, Pages 739-747

  Hawkins, Randall A ^a   Hoh, Carl K ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

CANCER DIAGNOSIS; CANCER THERAPY; CONFERENCE PAPER; HUMAN; POSITRON EMISSION TOMOGRAPHY;

DEOXYGLUCOSE; FLUDEOXYGLUCOSE F 18; FLUORINE RADIOISOTOPES; HUMAN; NEOPLASMS; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0028225687     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/0969-8051(94)90045-0     Document Type: Article

References (108)

1. Clinical assessment of therapeutic effects on cancer 18F-2-fluro-2-dexoy-d-glucose and positron emission tomography: preliminary study of lung cancer
2. Non-invasive grading of musculoskeletal tumors using PET
3. Evaluation of breast masses and axillary lymph nodes with [F-18]2-deoxy-2-fluoro-d-glucose PET
4. Positron emission tomography for in-vivo measurement of regional blood flow, oxygen utilization, and blood volume in patients with breast carcinoma
5. Positron emission tomography in the study of human tumors
6. Transformation of rat fibroblasts by FSV rapidly increases glucose transporter gene transcription
7. F-18 fluoride for bone imaging
8. Quantitative measurement of blood brain barrier permeability using rubidium-82 and positron emission tomography
9. Positron emission tomography with fluorodeoxyglucose to evaluate tumor response and control after radiation therapy
10. 18F]fluoride kinetics in humans
11. Single photon emission computed tomography and positron emission tomography in cancer imaging
12. In vivo kinetics of radiolabeled antibody: PET studies of I-124 labeled 3F8 MAB in human glioma
13. Evaluation of a positron emission tomography (PET) scanner for whole body imaging
14. 82Rb. I: error analysis and computer simulations
15. PET-FDG of untreated and treated cerebral gliomas
16. 18F]fluorodeoxyglucose and positron emission tomography
17. 18F-2-deoxyglucose in normal and pathological cases
18. Cerebral necrosis after radiotherapy and/or intra-arterial chemotherapy for brain tumors: PET and neuropathologic studies
19. 18F]fluorodeoxyglucose in brain tumors
20. Elevated levels of glucose transport and transporter messenger RNA are inducted by ras or src oncogenes
21. Clinical and biological significance of aneuploidy in human tumors
22. Relationship between histologic type of primary lung cancer and carbon-11-l-methionine uptake with positron emission tomography
23. 18F]fluoracetyl-d-glucosamine: a potential agent for cancer diagnosis
24. 18F]2-deoxyglucose
25. Quantitative scanning of osteogenic sarcoma with nitrogen-13-labeled l-glutamate
26. Characterization of a whole body imaging technique for PET
27. Solitary pulmonary nodules: detection of malignancy with PET with 2-[F-18]-fluoro-2-deoxy-d-glucose
28. PET studies of FDG metabolism in patient with recurrent colorectal tumors receiving radiotherapy
29. Glucose uptake, perfusion and cell proliferation in head and neck tumors: relation of positron emission tomography to flow cytometry
30. Applications of PET in clinical oncology
31. Effects of temporal sampling, glucose metabolic rates and disruptions of the blood barrier (BBB) on the FDG model with and without a vascular compartment: studies in human brain tumors with PET
32. 18F]fluoride ion with PET
33. Quantitating tumor glucose metabolism with FDG and PET
34. Role of PET in oncology and other whole body applications
35. PET cancer evaluations with FDG
36. 11C]leucine and PET: Methods, model and results in animals and humans
37. 68Ga EDTA and positron computed tomography
38. 11C]-deoxy-d-glucose
39. The regulation of glucose transporter gene expression by cyclic adenosine monophosphate in NIH3T3 fibroblasts
40. Growth factors rapidly induce expression of the glucose transporter gene
41. Cancer detection with whole body PET with 2-[F-18]fluoro-2-deoxy-d-glucose (FDG)
42. Noninvasive determination of local cerebral metabolic rate of glucose in man
43. 3H-deoxythymidine in tumor-bearing rats and mice
44. 15O and positron emission tomography: analytical techniques and preliminary results
45. 18F]-fluoro-2-deoxy-d-glucose (FDG) with MRI correlation
46. 82Rb: the effect of dexamethasone and whole-brain radiation therapy
47. Flow cytometric analysis of head and neck carcinoma DNA index and S-fraction from paraffin embedded sections: comparison with malignancy grading
48. Receptor-binding radiopharmacueticals for imaging breast tumors: estrogen-receptor interactions and selectivity of tissue uptake of halogenated estrogen analogs
49. In-vivo protein synthesis rates with leucyl-transfer RNA used as precursor pool: determination of biochemical parameters to structure tracer kinetic models for positron emission tomography
50. 68Ga]EDTA
51. 11C]methionine for measuring in vivo protein synthesis rates with PET
52. Nitrogen-13-glutamate uptake and perfusion in Walker 256 carcinosarcoma before and after single-dose-irradiation
53. n-13-l-glutamate uptake in malignancy: its relationship to blood flow
54. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole
55. 18F]fluorodeoxyglucose and positron emission tomography
56. Differential diagnosis of lung tumor with positron emission tomography: a prospective study
57. Comparison of C-11 methionine and F-18 fluorodeoxyglucose for the differential diagnosis of lung tumor
58. Rapid and sensitive response to carbon-11-l-methionine tumor uptake to irradiation
59. 11C]l-Methionine
60. A method to quantitate the fractional extraction of rubidium-82 across the blood brain barrier using positron emission tomography
61. In vivo measurement of carbon-11-thymidine uptake in non-Hodgkin's lymphoma using positron emission tomography
62. Attenuation correction in whole body PET
63. Quantitative evaluation of glucose utilization in liver metastases: parametric imaging with PET
64. 18F]fluorodeoxyglucose scintigraphy in diagnosis and follow up of treatment in advanced breast cancer
65. Evaluation of treatment response to radiotherapy in head and neck cancer with fluorine-18-fluorodeoxyglucose
66. Fluorodeoxyglucose imaging: a comparison with DNA flow cytometry in head and neck tumors
67. Breast cancer: PET imaging of estrogen receptors
68. Monoclonal antibodies and neuroblastoma
69. 11C-Methionine and computed tomography of intracranial tumour compared with histopathologic examination of multiple biopsies
70. Glucose utilization in vivo by human pulmonary neoplasms
71. The applications of positron emission tomography to oncology (ediotrial)
72. Prediction of survival in glioma patients by PET
73. Comparison of fluorine-18-2-Fluorodeoxy-glucose and gallium-67 citrate imaging for detection of lymphoma
74. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)-2-fluoro-2-deoxy-d-glucose: validation of method
75. 11C-labelled thymidine for tumor visualization using positron emission tomography
76. Radiolabeled fluromisonidazole as an imaging agent for tumor hypoxia
77. Charcteristics of the binding of labeled fluromisonidazole in cells in vitro
78. Skeletal blood flow, iliac histomorphometry, and strontium kinetics in osteroporosis: a relationship between blood flow and corrected apposition rate
79. Imaging of pulmonary mass lesions with whole body positron emission tomography and fluorodeoxyglucose
80. Change induced by radiation therapy in FDG uptake in normal and malignant structures of the head and neck: quantitation with PET
81. Imaging of primary Ewing sarcoma with N-13 l-glutamate
82. Quotient imaging with N-13 glutamate in osteogenic sarcoma
83. 18F)-flurodeoxyglucose method for the measurement of local cerebral glucose utilization in man
84. In vivo disturbance of the oxidative metabolism of glucose in human cerebral gliomas
85. Uptake of “N-ammonia by human tumors as studies by positron emission tomography”
86. 11C]thymidine labeled in the ring-2 and methylpositions
87. Utilization of labeled thymidine in DNA synthesis: studies for PET
88. Cancer statistics, 1987
89. Proteins antigenically related to the human erythrocyte glucose transporter in normal and Rous sarcoma virus-transformed chicken embryo fibroblasts.
90. 14C)-deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure and normal values in the conscious and anesthetized albion rat
91. Physical performance of the latest generation of commercial positron scanner
92. The applications of PET in clinical oncology
93. Recurrence of colorectal tumors: PET evaluation
94. Application of positron emission tomography with 2-[F-18]fluoro-2-deoxy-d-glucose (FDG) to the evaluation of breast masses
95. 18F-fluoro-2-deoxyuridine (FUdR) as a tracer of nucleic acid metabolism in brain tumors
96. Reduction of breast cancer mortality through mass screening with modern mammography
97. 18F]fluoro-d-glucose (FDG) for the detection of tumor involvement in lymph nodes
98. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-d-glucose
99. Active breast cancer ehmohormonotherapy sequentially assessed by FDG PET: early metabolic decreements precede tumor shrinkage
100. On the origin of cancer cells
101. Enzymology of cancer cells
102. Enzymology of cancer cells
103. Quantitative measurement of monoclonal antibody distribution and blood flow using positron emission tomography and 124iodine in patients with breast cancer
104. 19F NMR spectroscopic pharmaco-kinetics in tumor-bearing humans and rabbits
105. Radio-synthesis of fluorotamoxifen analogs
106. Brain tumor evaluation using Rb-82 and positron emission tomography